Urolithin A enhances chemotherapy efficacy and preserves intestinal barrier integrity in pancreatic ductal adenocarcinoma (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B128; "Background:Pancreatic ductal adenocarcinoma (PDAC) is commonly treated with standard chemotherapy regimens such as Gemcitabine/Paclitaxel (Gem+PTX) and FOLFIRINOX (FFX), which are cytotoxic agents...We investigated whether UroA could improve antitumor efficacy while protecting against chemotherapy-induced intestinal injury in preclinical PDAC models.We used genetically engineered PKT (Ptf1aCre/+; LSL-KrasG12D/+; Tgfbr2flox/flox) or orthotopically implanted KPC6694 cells in C57BL6 mice that were treated with vehicle, UroA, Gem+PTX, or (Gem+PTX)+UroA; parallel studies evaluated FFX±UroA and MRTX1133+(Gem+PTX)+UroA...Urolithin A enhances chemotherapy's antitumor activity, protects the intestinal barrier, and further extends survival when combined with KRAS inhibition, supporting UroA as a translationally ready PDAC-combination adjuvant.Citation Format:Varunkumar Krishnamoorthy, Vineet K. Gupta, Nitu R. Heggade, Siddharth Mehra, Sweta Ghosh, Sana I...."
Clinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS • TJP1
|
|
Varunkumar Krishnamoorthy; Vineet K. Gupta; Nitu R. Heggade; Siddharth Mehra; Sweta Ghosh; Sana I. Oroumieh; Daysi D. Manrique; Rohan Moniruzzaman; Kamalpreet K. Sandha; Sanjana Shrivatsa; Rimpi Khurana; Venkatakrishna R. Jala; Yuguang Ban; Nipun Merchant; Austin R. Dosch; Peter J. Hosein; Nagaraj Nagathihalli
|